Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Marc Peeters, Timothy Price, Michael Boedigheimer, Tae Won Kim, Paul Ruff, Peter Gibbs, Anne Thomas, Gaston Demonty, Kristina Hool, Agnes Ang
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019
PURPOSE: Mutations in EGFR pathway genes are poor prognostic indicators in patients with metastatic colorectal cancer. Plasma analysis of cell-free DNA is a minimally invasive and highly sensitive method to detect somatic mutations in tumors. EXPERIMENTAL DESIGN: Plasma samples collected from panitumumab-treated patients in the ASPECCT study at baseline and safety follow-up (SFU) were analyzed by a next-generation sequencing-based approach for extended RAS mutant allele frequency as a continuous variable and their association with clinical outcomes and the mutational prevalence of 63 cancer-related genes. The correlation between patient outcome and baseline mutational status of EGFR pathway ..View full abstract
We thank Yang Li, PhD (Amgen Inc.), for medical writing support. This work was supported by Amgen Inc.